A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (FINN)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Non-small Cell Lung Cancer (NSCLC)

Treatments: Drug: Nivolumab + ipilimumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06487156

CA209-1409

Details and patient eligibility

About

The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of stage IV or recurrent NSCLC (histologically or cytologically confirmed stage), without known EGFR- or ALK-alterations
• Decision to initiate a first-line treatment with nivolumab plus ipilimumab for the treatment of NSCLC according to the Italy label has been made independently of the study
• Patient is at least 18 years of age at time of treatment decision
• Patient provided written informed consent to participate in the study

Exclusion criteria

• Current primary diagnosis of a cancer other than NSCLC that requires systemic or other treatment
• Patients with known EGFR- or ALK-alterations
• Previous treatment with nivolumab and/or ipilimumab
• Patient already included in an interventional clinical trial for their advanced or recurrent NSCLC (but: Patients who have completed their participation in an interventional trial, who are not receiving study drug any more, and who are only followed-up for OS, can be enrolled)

Trial design

400 participants in 1 patient group

Participants receiving first-line nivolumab plus ipilimumab

Treatment:

Drug: Nivolumab + ipilimumab